title: Author's reply to comments to: Clinical experience of switching anti-VEGF therapy from ranimizumab to aflibercept in age-related choroidal neovascularization.
authors.affiliation: Moorfields Hospital NHS Trust, Croydon University Hospital London, Surrey - UK.
authors.forename: George
authors.initials: G
authors.lastname: Kampougeris
mesh_terms: D000068258:Bevacizumab; D020256:Choroidal Neovascularization; D006801:Humans; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A
chemical_list: D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor